Stock Events

Veru 

€0.85
134
-€0.06-6.95% Friday 06:03

Statistics

Day High
0.85
Day Low
0.85
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
127.52M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.51
-0.36
-0.2
-0.05
Expected EPS
-0.05
Actual EPS
-0.07

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FMW.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap163.88B
Pfizer is a global pharmaceutical company that competes with Veru in the development of treatments for various diseases, including those in Veru's portfolio.
Merck &
MRK
Mkt Cap323.59B
Merck is involved in the research, development, manufacturing, and marketing of pharmaceuticals that directly compete with Veru's cancer and infectious disease treatments.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences competes with Veru in the area of antiviral drugs, including treatments for HIV, hepatitis B, hepatitis C, and influenza.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie operates in similar therapeutic areas as Veru, including oncology, making it a direct competitor in the pharmaceutical market.
Bristol-Myers Squibb
BMY
Mkt Cap82.02B
Bristol Myers Squibb is a global biopharmaceutical company that develops prescription drugs in several therapeutic areas, including cancer, competing with Veru's oncology products.
AMGEN
AMGN
Mkt Cap177.47B
Amgen focuses on human therapeutics, including treatments for cancer and other serious illnesses, which puts it in competition with Veru.
Johnson & Johnson
JNJ
Mkt Cap360.71B
Johnson & Johnson, through its pharmaceutical segment, competes with Veru in developing drugs for various diseases, including cancer and infectious diseases.
Astrazeneca
AZN
Mkt Cap245.69B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company that competes with Veru in developing treatments for cancer and other diseases.
Novartis
NVS
Mkt Cap244.62B
Novartis is a global healthcare company that competes with Veru in the research and development of innovative medicines, particularly in oncology.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, competing with Veru in developing treatments for serious medical conditions, including cancer.

About

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Show more...
CEO
Dr. Mitchell S. Steiner F.A.C.S., M.D.
Employees
189
Country
US
ISIN
US92536C1036
WKN
000A2DV3C

Listings